Solid Phase Extraction HLB Cartridges, 60 mg, 3 mL with DEC Caps
ID: HFP-2025-129641Type: Sources Sought
Overview

Buyer

DEPARTMENT OF HEALTH AND HUMAN SERVICESFOOD AND DRUG ADMINISTRATIONFOOD AND DRUG ADMINISTRATIONROCKVILLE, MD, 20857, USA

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

PSC

ANALYSIS INSTRUMENTS, MEDICAL LABORATORY USE (6632)

Set Aside

No Set aside used (NONE)
Timeline
    Description

    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking sources for Solid Phase Extraction HLB Cartridges, 60 mg, 3 mL with DEC Caps for its Arkansas Human and Animal Food Laboratory. The FDA requires 7,000 cartridges that are validated for use on regulatory samples, specifically for analyzing chloramphenicol and nitrofurans in aquaculture species, utilizing the Gilson GX-274 automated solid phase extraction system. These cartridges are critical for the laboratory's routine analysis of over 6,000 subsamples annually, supporting the FDA’s antibiotics in aquaculture program. Interested vendors, particularly small businesses under NAICS Code 334516, must submit capability statements, including business overviews and past performance, by August 17, 2025, to David Kramer at david.kramer@fda.hhs.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The FDA is conducting market research for Solid Phase Extraction HLB Cartridges, 60 mg, 3 mL with DEC Caps (HFP-2025-129641) for its Arkansas Human and Animal Food Laboratory. These cartridges are essential consumables for analyzing over 6,000 subsamples annually for chloramphenicol and nitrofurans in aquaculture species using Gilson GX-274 systems. The FDA seeks small and other than small businesses under NAICS Code 334516 (Analytical Laboratory Instrument Manufacturing) to provide 7,000 cartridges meeting specific characteristics, including a particle size of 25.0-35.0 µm and OEM compatibility with the Gilson GX-274 system. Responses must include business overview, descriptive literature, three years of past performance, and capabilities for delivery, accessibility, and Buy American Act compliance. Informational pricing is encouraged. Capability statements are due by August 17, 2025, at 13:00 CT to david.kramer@fda.hhs.gov. This market research will inform future procurement strategies, potentially leading to a pre-solicitation synopsis and solicitation.
    Lifecycle
    Title
    Type
    Similar Opportunities
    Loading similar opportunities...